Polycystic ovary syndrome

New England Journal of Medicine

Volumn 333, Issue 13, 1995, Pages 853-861

  Franks, Stephen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; CLOMIFENE CITRATE; ESTRADIOL; FOLLITROPIN; GROWTH HORMONE; LUTEINIZING HORMONE; PROLACTIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ANOVULATION; CALORIC RESTRICTION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DYSLIPIDEMIA; GENETICS; HIRSUTISM; HYPERANDROGENISM; INSULIN RESISTANCE; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYNDROME; FEMALE; HUMAN; PATHOPHYSIOLOGY;

ANOVULATION; DIAGNOSIS, DIFFERENTIAL; FEMALE; HIRSUTISM; HUMAN; POLYCYSTIC OVARY SYNDROME;

EID: 0029095150     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199509283331307     Document Type: Review

References (140)

1. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Polycystic ovary syndrome. Oxford, England: Blackwell Scientific, 1992:377-84.
2. Stein IF, Leventhal ML Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29: 181-191
3. Goldzieher JW, Green JA The polycystic ovary. 1. Clinical and histological features. J Clin Endocrinol Metab 1962; 22: 325-338
4. Yen SSC, Vela P, Rankin J Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease. J Clin Endocrinol Metab 1970; 30: 435-442
5. McArthur JW, Ingersoll FM, Worcester J The urinary excretion of interstitial-cell and follicle-stimulating hormone activity by women with diseases of the reproductive system. J Clin Endocrinol Metab 1958; 18: 1202-1215
6. Gambrell RD Jr, Greenblatt RB, Mahesh VB Inappropriate secretion of LH in the Stein-Leventhal syndrome. Obstet Gynecol 1973; 42: 429-440
7. Holte J, Bergh T, Gennarelli G, Wide L The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women. Clin Endocrinol (Oxf) 1994; 41: 473-481
8. Swanson M, Sauerbrei EE, Cooperberg PL Medical implications of ultrasonically detected polycystic ovaries. J Clin Ultrasound 1981; 9: 219-222
9. Parisi L, Tramonti M, Derchi LE, Casciano S, Zurli A, Rocchi P Polycystic ovarian disease: ultrasonic evaluation and correlations with clinical and hormonal data. J Clin Ultrasound 1984; 12: 21-26
10. Adams J, Franks S, Polson DW, Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet 1985; 2: 1375-1379
11. Yeh HC, Futterweit W, Thornton JC Polycystic ovarian disease: US features in 104 patients. Radiology 1987; 163: 111-116
12. Pache TD, Hop WC, Wladimiroff JW, Schipper J, Fauser BC Transvaginal sonography and abnormal ovarian appearance in menstrual cycle disturbances. Ultrasound Med Biol 1991; 17: 589-593
13. Adams J, Polson DW, Franks S Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. BMJ 1986; 293: 355-359
14. Franks S Polycystic ovary syndrome: a changing perspective. Clin Endocrinol (Oxf) 1989; 31: 87-120
15. Jacobs HS Polycystic ovaries and polycystic ovary syndrome. Gynecol Endocrinol 1987; 1: 113-131
16. Fox R, Corrigan E, Thomas PA, Hull MG The diagnosis of polycystic ovaries in women with oligo-amenorrhoea: predictive power of endocrine tests. Clin Endocrinol (Oxf) 1991; 34: 127-131
17. Takahashi K, Yoshino K, Nishigaki A, Eda Y, Kitao M On the relationship between endocrine and ovulatory abnormalities, and polycystic ovaries as diagnosed by ultrasonography. Int J Fertil 1992; 37: 222-226
18. Hull MG Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol Endocrinol 1987; 1: 235-245
19. Conway GS, Honour JW, Jacobs HS Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin Endocrinol (Oxf) 1989; 30: 459-470
20. O'Driscoll JB, Mamtora H, Higginson J, Pollock A, Kane J, Anderson DC A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients with hirsutism or androgenic alopecia. Clin Endocrinol (Oxf) 1994; 41: 231-236
21. Bunker CB, Newton JA, Conway GS, Jacobs HS, Greaves MW, Dowd PM The hormonal profile of women with acne and polycystic ovaries. Clin Exp Dermatol 1991; 16: 420-423
22. Eden JA The polycystic ovary syndrome presenting as resistant acne successfully treated with cyproterone acetate. Med J Aust 1991; 155: 677-680
23. Yen SSC The polycystic ovary syndrome. Clin Endocrinol (Oxf) 1980; 12: 177-207
24. Polson DW, Adams J, Wadsworth J, Franks S Polycystic ovaries -- a common finding in normal women. Lancet 1988; 1: 870-872
25. Ferriman D, Gallwey JD Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21: 1440-1447
26. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 1987; 65: 499-507
27. New MI. Nonclassical 21-hydroxylase deficiency. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Polycystic ovary syndrome. Oxford, England: Blackwell Scientific, 1992:145-61.
28. Hague WM, Honour JW, Adams J, Vecsei P, Jacobs HS Steroid responses to ACTH in women with polycystic ovaries. Clin Endocrinol (Oxf) 1989; 30: 355-365
29. Waldstreicher J, Santoro NF, Hall JE, Filicori M, Crowley WF Jr Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab 1988; 66: 165-172
30. Fauser BC, Pache TD, Lamberts SW, Hop WC, de Jong FH, Dahl KD Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease. J Clin Endocrinol Metab 1991; 73: 811-817
31. Fauser BC, Pache TD, Hop WC, de Jong FH, Dahl KD The significance of a single serum LH measurement in women with cycle disturbances: discrepancies between immunoreactive and bioactive hormone estimates. Clin Endocrinol (Oxf) 1992; 37: 445-452
32. Barth JH Alopecia and hirsuties: current concepts in pathogenesis and management. Drugs 1988; 35: 83-91
33. Lobo RA Hirsutism in polycystic ovary syndrome: current concepts. Clin Obstet Gynecol 1991; 34: 817-826
34. Carmina E, Koyama T, Chang L, Stanczyk FZ, Lobo RA Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol 1992; 167: 1807-1812
35. Bardin CW, Lipsett MB Testosterone and androstenedione blood production rates in normal women and women with idiopathic hirsutism or polycystic ovaries. J Clin Invest 1967; 46: 891-902
36. Kirschner MA, Bardin CW Androgen production and metabolism in normal and virilized women. Metabolism 1972; 21: 667-688
37. Kirschner MA, Samojlik E, Silber D A comparison of androgen production and clearance in hirsute and obese women. J Steroid Biochem 1983; 19: 607-614
38. Anderson DC Sex-hormone-binding globulin. Clin Endocrinol (Oxf) 1974; 3: 69-96
39. Rosner W The functions of corticosteroid-binding globulin and sex hormone-binding globulin: recent advances. Endocr Rev 1990; 11: 80-91
40. Kiddy DS, Sharp PS, White DM, Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol (Oxf) 1990; 32: 213-220
41. Kiddy DS, Hamilton-Fairley D, Seppala M, Diet-induced changes in sex hormone-binding globulin and free testosterone in women with normal and polycystic ovaries: correlation with serum insulin and insulin-like growth factor-I. Clin Endocrinol (Oxf) 1989; 31: 757-763
42. Nestler JE, Strauss J III Insulin as an effector of human ovarian and adrenal steroid metabolism. Endocrinol Metab Clin North Am 1991; 20: 807-823
43. Pugeat M, Crave JC, Elmidani M, Pathophysiology of sex hormone binding globulin (SHBG): relation to insulin. J Steroid Biochem Mol Biol 1991; 40: 841-849
44. Plymate SR, Matej LA, Jones RE, Friedl KE Inhibition of sex hormone-binding globulin production in human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 1988; 67: 460-464
45. Singh A, Hamilton-Fairley D, Koistinen R, Effect on insulin-like growth factor-type I (IGF-I) and insulin on the secretion of sex hormone binding globulin and IFG-I binding protein I (IBP-I) by human hepatoma cells. J Endocrinol 1990; 124: R1-R3
46. Scanlon MJ, Whorwood CB, Franks S, Reed MJ, James VH Serum androstanediol glucuronide concentrations in normal and hirsute women and patients with thyroid dysfunction. Clin Endocrinol (Oxf) 1988; 29: 529-538
47. Thompson DL, Horton N, Rittmaster RS Androsterone glucuronide is a marker of adrenal hyperandrogenism in hirsute women. Clin Endocrinol (Oxf) 1990; 32: 283-292
48. Polson DW, Franks S, Reed MJ, Cheng RW, Adams J, James VH The distribution of oestradiol in plasma in relation to uterine cross-sectional area in women with polycystic or multifollicular ovaries. Clin Endocrinol (Oxf) 1987; 26: 581-588
49. Sherman AI, Brown S The precursors of endometrial carcinoma. Am J Obstet Gynecol 1979; 135: 947-956
50. Menashe Y, Lunenfeld B, Pariente C, Frenkel Y, Mashiach S Can growth hormone increase, after clonidine administration, predict the dose of human menopausal hormone needed for induction of ovulation? Fertil Steril 1990; 53: 432-435
51. Kazer RR, Unterman TG, Glick RP An abnormality of the growth hormone/insulin-like growth factor-I axis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1990; 71: 958-962
52. Slowinska-Srzednicka J, Zgliczynski W, Makowska A, An abnormality of the growth hormone/insulin-like growth factor-I axis in women with polycystic ovary syndrome due to coexistent obesity. J Clin Endocrinol Metab 1992; 74: 1432-1435
53. Futterweit W Pituitary tumors and polycystic ovarian disease. Obstet Gynecol 1983; 62: Suppl: 74s-79s
54. Luciano AA, Chapler FK, Sherman BM Hyperprolactinemia in polycystic ovary syndrome. Fertil Steril 1984; 41: 719-725
55. Murdoch AP, Dunlop W, Kendall-Taylor P Studies of prolactin secretion in polycystic ovary syndrome. Clin Endocrinol (Oxf) 1986; 24: 165-175
56. Chang RJ, Geffner ME Associated non-ovarian problems of polycystic ovarian disease: insulin resistance. Clin Obstet Gynecol 1985; 12: 675-685
57. Moller DE, Flier JS Insulin resistance -- mechanisms, syndromes, and implications. N Engl J Med 1991; 325: 938-948
58. Dunaif A. Insulin resistance and ovarian dysfunction. In: Moller D, ed. Insulin resistance. New York: John Wiley, 1993:301-25.
59. Burghen GA, Givens JR, Kitabachi AE Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980; 50: 113-116
60. Shoupe D, Kumar DD, Lobo RA Insulin resistance in polycystic ovary syndrome. Am J Obstet Gynecol 1983; 147: 588-592
61. Chang RJ, Nakamura RM, Judd HL, Kaplan SA Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983; 57: 356-359
62. Conway GS, Jacobs HS, Holly JMP, Wass JAH Effects of luteinizing hormone, insulin, insulin-like growth factor-I and insulin-like growth factor small binding protein 1 in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1990; 33: 593-603
63. Dunaif A, Segal KR, Futterweit W, Dobrjansky A Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165-1174
64. Peiris AN, Aiman EJ, Drucker WD, Kissebah AH The relative contributions of hepatic and peripheral tissues to insulin resistance in hyperandrogenic women. J Clin Endocrinol Metab 1989; 68: 715-720
65. Robinson S, Chan SP, Spacey S, Anyaoku V, Johnston DG, Franks S Postprandial thermogenesis is reduced in polycystic ovary syndrome and is associated with increased insulin resistance. Clin Endocrinol (Oxf) 1992; 36: 537-543
66. Evans DJ, Barth JH, Burke CW Body fat topography in women with androgen excess. Int J Obes 1988; 12: 157-162
67. Nestler JE, Clore JN, Blackard WG The central role of obesity (hyperinsulinemia) in the pathogenesis of the polycystic ovary syndrome. Am J Obstet Gynecol 1989; 161: 1095-1097
68. Pasquali R, Casimirri F, Balestra V, The relative contribution of androgens and insulin in determining abdominal body fat distribution in premenopausal women. J Endocrinol Invest 1991; 14: 839-846
69. Bouchard C, Despres JP, Mauriege P Genetic and nongenetic determinants of regional fat distribution. Endocr Rev 1993; 14: 72-93
70. Barbieri RL, Makris A, Ryan KJ Insulin stimulates androgen accumulation in incubations of human ovarian stroma and theca. Obstet Gynecol 1984; 64: Suppl: 73S-80S
71. Bergh C, Carlsson B, Olsson JH, Selleskog U, Hillensjo T Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. Fertil Steril 1993; 59: 323-331
72. Poretsky L, Kalin MF The gonadotropic function of insulin. Endocr Rev 1987; 8: 132-141
73. Dunaif A, Mandeli J, Fluhr H, Dobrjansky A The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome. J Clin Endocrinol Metab 1988; 66: 131-139
74. Sharp PS, Kiddy DS, Reed MJ, Anyaoku V, Johnston DG, Franks S Correlation of plasma insulin and insulin-like growth factor-I with indices of androgen transport and metabolism in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1991; 35: 253-257
75. Toscano V, Bianchi P, Balducci R, Lack of linear relationship between hyperinsulinaemia and hyperandrogenism. Clin Endocrinol (Oxf) 1992; 36: 197-202
76. Temple RC, Clark PMS, Nagi DK, Schneider AE, Yudkin JS, Hales CN Radioimmunoassay may overestimate insulin in non-insulin-dependent diabetics. Clin Endocrinol (Oxf) 1990; 32: 689-693
77. Conway GS, Clark PM, Wong D Hyperinsulinaemia in the polycystic ovary syndrome confirmed with a specific immunoradiometric assay for insulin. Clin Endocrinol (Oxf) 1993; 38: 219-222
78. Flier JS, Eastman RC, Minaker KL, Matteson D, Rowe JW Acanthosis nigricans in obese women with hyperandrogenism: characterization of an insulin-resistant state distinct from the type A and B syndromes. Diabetes 1985; 34: 101-107
79. Jialal I, Naiker P, Reddi K, Moodley J, Joubert SM Evidence for insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1987; 64: 1066-1069
80. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992; 41: 1257-1266
81. Ciaraldi TP, el-Roeiy A, Madar Z, Reichart D, Olefsky JM, Yen SSC Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab 1992; 75: 577-583
82. Rosenbaum D, Haber RS, Dunaif A Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes. Am J Physiol 1993; 264: E197-E202
83. Robinson S, Kiddy D, Gelding SV, The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin Endocrinol (Oxf) 1993; 39: 351-355
84. Valdes CT, Elkind-Hirsch KE Intravenous glucose tolerance test-derived insulin sensitivity changes during the menstrual cycle. J Clin Endocrinol Metab 1991; 72: 642-646
85. Geffner ME, Kaplan SA, Bersch N, Golde DW, Landaw EM, Chang RJ Persistence of insulin resistance in polycystic ovarian disease after inhibition of ovarian steroid secretion. Fertil Steril 1986; 45: 327-333
86. Dunaif A, Green G, Futterweit W, Dobrjansky A Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1990; 70: 699-704
87. Dale PO, Tanbo T, Djoseland O, Jervell J, Abyholm T Persistence of hyperinsulinemia in polycystic ovary syndrome after ovarian suppression by gonadotropin-releasing hormone agonist. Acta Endocrinol (Copenh) 1992; 126: 132-136
88. Kiddy DS, Hamilton-Fairley D, Bush A, Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992; 36: 105-111
89. Mattsson LA, Cullberg G, Hamberger L, Samsioe G, Silfverstolpe G Lipid metabolism in women with polycystic ovary syndrome: possible implications for an increased risk of coronary heart disease. Fertil Steril 1984; 42: 579-584
90. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985; 61: 946-951
91. Wild RA, Bartholomew MJ The influence of body weight on lipoprotein lipids in patients with polycystic ovary syndrome. Am J Obstet Gynecol 1988; 159: 423-427
92. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992; 37: 119-125
93. Dahlgren E, Johansson S, Lindstedt G, Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 1992; 57: 505-513
94. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective study of women. Acta Obstet Gynecol Scand 1992; 71: 599-604
95. Franks S The ubiquitous polycystic ovary. J Endocrinol 1991; 129: 317-319
96. Stanhope R, Adams J, Pringle JP, Jacobs HS, Brook CG The evolution of polycystic ovaries in a girl with hypogonadotropic hypogonadism before puberty and during puberty induced with pulsatile gonadotropin-releasing hormone. Fertil Steril 1987; 47: 872-875
97. Chang RJ, Laufer LR, Meldrum DR, Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab 1983; 56: 897-903
98. Couzinet B, Le Strat N, Brailly S, Schaison G Comparative effects of cyproterone acetate or a long-acting gonadotropin-releasing hormone agonist in polycystic ovarian disease. J Clin Endocrinol Metab 1986; 63: 1031-1035
99. Steingold K, De Ziegler D, Cedars M, Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease. J Clin Endocrinol Metab 1987; 65: 773-778
100. Gilling-Smith C, Willis DS, Beard RW, Franks S Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab 1994; 79: 1158-1165
101. Rosenfield RL, Barnes RB, Cara JF, Lucky AW Dysregulation of cytochrome P450c 17 alpha as the cause of polycystic ovarian syndrome. Fertil Steril 1990; 53: 785-791
102. White DW, Leigh A, Wilson C, Donaldson A, Franks S Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1995; 42: 475-481
103. Carey AH, Waterworth D, Patel K, Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994; 3: 1873-1876
104. Ehrmann DA, Rosenfield RL, Barnes RB, Brigell DF, Sheikh Z Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 1992; 327: 157-162
105. Cooper HE, Spellacy WN, Prem KA, Cohen WD Hereditary factors in the Stein-Leventhal syndrome. Am J Obstet Gynecol 1968; 100: 371-387
106. Ferriman D, Purdie AW The inheritance of polycystic ovarian disease and a possible relationship to premature balding. Clin Endocrinol (Oxf) 1979; 11: 291-300
107. Givens JR Familial polycystic ovarian disease. Endocrinol Metab Clin North Am 1988; 17: 771-783
108. Hague WM, Adams J, Reeders ST, Peto TE, Jacobs HS Familial polycystic ovaries: a genetic disease? Clin Endocrinol (Oxf) 1988; 29: 593-605
109. Lunde O, Magnus P, Sandvik L, Hoglo S Familial clustering in the polycystic ovarian syndrome. Gynecol Obstet Invest 1989; 28: 23-30
110. Simpson JL. Elucidating the genetics of polycystic ovary syndrome. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Polycystic ovary syndrome. Oxford, England: Blackwell Scientific, 1992:59-77.
111. Carey AH, Chan KL, Short F, White DM, Williamson R, Franks S Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. Clin Endocrinol (Oxf) 1993; 38: 653-658
112. Nestler JE, Clore JN, Blackard WG. Effects of insulin on steroidogenesis in vivo. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Polycystic ovary syndrome. Oxford, England: Blackwell Scientific, 1992:265-78.
113. Franks S, Adams J, Mason H, Polson D Ovulatory disorders in women with polycystic ovary syndrome. Clin Obstet Gynaecol 1985; 12: 605-632
114. Hull MGR. The causes of infertility and relative effectiveness of treatment. In: Templeton AA, Drife JO, eds. Infertility. London: Springer-Verlag, 1992:33-62.
115. Franks S. Induction of ovulation. In: Templeton AA, Drife JO, eds. Infertility. London: Springer-Verlag, 1992:237-50.
116. Lunenfeld B, Insler V. Diagnosis and treatment of functional infertility. Berlin, Germany: Gross-Verlag, 1978.
117. Wang CF, Gemzell C The use of human gonadotropins for induction of ovulation in women with polycystic ovarian disease. Fertil Steril 1980; 33: 479-486
118. Hamilton-Fairley D, Franks S Common problems in induction of ovulation. Baillieres Clin Obstet Gynaecol 1990; 4: 609-625
119. Kamrava MM, Seibel MM, Berger MJ, Thompson I, Taymor ML Reversal of persistent anovulation in polycystic ovarian disease by administration of chronic low-dose follicle-stimulating hormone. Fertil Steril 1982; 37: 520-523
120. Polson DW, Mason HD, Saldahna MB, Franks S Ovulation of a single dominant follicle during treatment with low-dose pulsatile follicle stimulating hormone in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1987; 26: 205-212
121. Sagle MA, Hamilton-Fairley D, Kiddy DS, Franks S A comparative, randomized study of low-dose human menopausal gonadotropin and follicle-stimulating hormone in women with polycystic ovarian syndrome. Fertil Steril 1991; 55: 56-60
122. Hamilton-Fairley D, Kiddy D, Watson H, Sagle M, Franks S Low-dose gonadotrophin therapy for induction of ovulation in 100 women with polycystic ovary syndrome. Hum Reprod 1991; 6: 1095-1099
123. Shoham Z, Patel A, Jacobs HS Polycystic ovarian syndrome: safety and effectiveness of stepwise and low-dose administration of purified follicle-stimulating hormone. Fertil Steril 1991; 55: 1051-1056
124. Brown JB Pituitary control of ovarian function -- concepts derived from gonadotrophin therapy. Aust N Z J Obstet Gynaecol 1978; 18: 46-54
125. Wilshire GB, Santoro N. Appropriate regimens of pulsatile gonadotropin-releasing hormone (GnRH) administration. In: Filicori M, Flamigni C, eds. Ovulation induction: basic science and clinical advances. Amsterdam: Excerpta Medica, 1994:245-53.
126. Jacobs HS. Pulsatile GnRH in multifollicular and polycystic ovary patients. In: Filicori M, Flamigni C, eds. Ovulation induction: basic science and clinical advances. Amsterdam: Excerpta Medica, 1994:267-74.
127. Hamilton-Fairley D, Kiddy D, Watson H, Paterson C, Franks S Association of moderate obesity with a poor pregnancy outcome in women with polycystic ovary syndrome treated with low dose gonadotrophin. Br J Obstet Gynaecol 1992; 99: 128-131
128. Kopelman PG, White N, Pilkington TRE, Jeffcoate SL The effect of weight loss on sex steroid secretion and binding in massively obese women. Clin Endocrinol (Oxf) 1981; 15: 113-116
129. Harlass FE, Plymate SR, Fariss BL, Belts RP Weight loss is associated with correction of gonadotropin and sex steroid abnormalities in the obese anovulatory female. Fertil Steril 1984; 42: 649-651
130. Pasquali R, Antenucci D, Casimirri F, Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989; 68: 173-179
131. Gjonnaess H A simple treatment for polycystic ovarian syndrome. World Health Forum 1990; 11: 214-217
132. Armar NA, McGarrigle HH, Honour J, Holownia P, Jacobs HS, Lachelin GC Laparoscopic ovarian diathermy in the management of anovulatory infertility in women with polycystic ovaries: endocrine changes and clinical outcome. Fertil Steril 1990; 53: 45-49
133. Abdel Gadir A, Mowafi RS, Alnaser HM, Alrashid AH, Alonezi OM, Shaw RW Ovarian electrocautery versus human menopausal gonadotrophins and pure follicle stimulating hormone therapy in the treatment of patients with polycystic ovarian disease. Clin Endocrinol (Oxf) 1990; 33: 585-592
134. Gurgan T, Kisnisci H, Yarali H, Develioglu O, Zeyneloglu H, Aksu T Evaluation of adhesion formation after laparoscopic treatment of polycystic ovarian disease. Fertil Steril 1991; 56: 1176-1178
135. Miller JA, Jacobs HS Treatment of hirsutism and acne with cyproterone acetate. Clin Endocrinol Metab 1986; 15: 373-389
136. Reed MJ, Franks S Anti-androgens in gynaecological practice. Baillieres Clin Obstet Gynaecol 1988; 2: 581-595
137. Barth JH, Cherry CA, Wojnarowska F, Dawber RP Spironolactone is an effective and well tolerated systemic antiandrogen therapy for hirsute women. J Clin Endocrinol Metab 1989; 68: 966-970
138. Cusan L, Dupont A, Belanger A, Tremblay RR, Manhes G, Labrie F Treatment of hirsutism with the pure antiandrogen flutamide. J Am Acad Dermatol 1990; 23: 462-469
139. Cusan L, Dupont A, Gomez JL, Tremblay RR, Labrie F Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril 1994; 61: 281-287
140. Hammerstein J, Moltz L, Schwartz U Antiandrogens in the treatment of acne and hirsutism. J Steroid Biochem 1983; 19: 591-597